Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. November 2020 08:00 ET | Quelle: iCAD, Inc.

iCAD Reports Over 1,000 Licenses Sold as Part of ProFound AI Sales

Significant Percentage of Licenses Sold to Facilities with GE, Siemens, and Sites with Multiple Vendors Including Hologic and Fuji ProFound AI for DBT Offers Superior Clinical Performance When...
05. November 2020 16:01 ET | Quelle: iCAD, Inc.

iCAD Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020

Achieved Sequential Revenue Growth of 28% in Third Quarter of 2020, Driven by Detection Product and Therapy Product Revenue Growth of 44% and 251%, Respectively Net Loss Improved by $1.2 million to...
29. Oktober 2020 08:27 ET | Quelle: iCAD, Inc.

iCAD to Report Third Quarter 2020 Financial Results on Thursday, November 5

NASHUA, N.H., Oct. 29, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it...
23. Oktober 2020 17:01 ET | Quelle: iCAD, Inc.

New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological Cancers

NASHUA, N.H., Oct. 23, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company...
20. Oktober 2020 08:00 ET | Quelle: iCAD, Inc.

iCAD Signs Distribution Agreement with Change Healthcare

NASHUA, N.H., Oct. 20, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it has...
19. Oktober 2020 08:00 ET | Quelle: iCAD, Inc.

New Data Supports iCAD’s Xoft Brain IORT as Feasible Treatment for Recurrent Glioblastoma

NASHUA, N.H., Oct. 19, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that new,...
16. Oktober 2020 08:00 ET | Quelle: iCAD, Inc.

iCAD Hosting Technology Innovation Webinar on the Evolving Landscape for Treating Patients with Brain, Breast, and Rectal Cancers

NASHUA, N.H., Oct. 16, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it...
20. September 2020 21:00 ET | Quelle: iCAD, Inc.

iCAD Responds to CMS’ Finalized Radiation Oncology Alternative Payment Model

NASHUA, N.H., Sept. 20, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, is providing additional...
18. September 2020 16:29 ET | Quelle: iCAD, Inc.

iCAD’s IORT Excluded from CMS’s Radiation Oncology Alternative Payment Model

Existing Reimbursement Codes Will Still Apply in All Geographic MarketsiCAD Intends to Submit Additional Long-Term Data in Support of IORT’s Inclusion and Petition CMS for Reconsideration NASHUA,...
15. September 2020 08:00 ET | Quelle: iCAD, Inc.

iCAD Announces Compelling Data Supporting Launch of First and Only Commercially Available Technology to Provide Short-Term Breast Cancer Risk Assessment

ProFound AI Risk allows for detection of cancers between screenings based on data from prestigious academic medical center, Karolinska Institutet Research published in Radiology shows technology...

Vorherige Seite

Nächste Seite